July 7, 2022

Katie Edmiston

CAZENOVIA, NY – NCODA is pleased to announce the appointment of three oncology leaders to the Executive Council: Meg Butler, PharmD (Clearview Cancer Institute), Gury Doshi, MD (Texas Oncology), and Xylina Gregg, MD (Utah Cancer Specialists). “Our Executive Council is comprised of a dedicated team of oncology leaders committed to providing insight, education, and innovation that improves patient care and empowers the medically-integrated practice,” said Randy Erickson, RN, BSN, MBA, CEO of Utah Cancer Specialists and Chair of the NCODA Executive Council. “With the addition of Dr. Gregg, Dr. Doshi and Meg to the Executive Council, NCODA is further strengthened to progress into the future while creating true transformation in oncology patient care.” 

The NCODA Executive Council has been instrumental in facilitating a strong path forward for patient-centered and collaborative oncology care. “We’re excited to expand our Council with three new members who will bring diverse expertise and insight to our Mission,” said Michael Reff, RPh, MBA, Founder and Executive Director of NCODA. “NCODA’s Executive Council consists of leaders from our member practices. Added together, the Council brings a wealth of experience which allows for significant strides in our efforts to improve oncology patient care.” 

About the new Executive Council members:

Meg Bulter, PharmD, is a Huntsville native who received a BS in Biomedical Science and a minor in Italian from Auburn University. She received her Doctor of Pharmacy from Harrison School of Pharmacy in 2011. After graduation, she moved back to Huntsville and began working as a pharmacist for CVS in the Madison / Huntsville area. In 2015, Meg left CVS and joined Clearview Cancer Institute as a staff pharmacist. In 2019, Meg took over as Ambulatory Pharmacy Manager at CCI. Along with managing the specialty retail pharmacy at CCI, Meg works diligently with the director of pharmacy managing the IV pharmacies, answering clinical questions and building / improving regimens and treatment plans in the EMR at CCI.

Gurjyot “Gury” K. Doshi, MD, is a physician at Texas Oncology. Prior to joining Texas Oncology in 2010, Dr. Doshi was an assistant professor in the Division of Oncology at The University of Texas in the Texas Medical Center. Dr. Gury Doshi is associate chair of the genitourinary committee of US Oncology Research. She joined the genitourinary committee program in 2012 and has quickly risen as a leader serving as US Oncology Research principal investigator for multiple studies and as a top enroller to clinical trials year after year. Her special interest is in treatment of genitourinary tumors; prostate, kidney and bladder cancers. Dr. Doshi’s research publications include a review on sequencing therapies in metastatic renal cell carcinoma, and the use of morphoproteomic analysis to determine selection of therapy in kidney cancer. 

Xylina Gregg, MD, is a physician partner at Utah Cancer Specialists (UCS) in Salt Lake City, Utah, and is Medical Director for UCS’ Laboratory and Imaging Services. She is the current President of the Society of Utah Medical Oncologists (SUMO), and is the 2022-23 Chair of the ASCO State Affiliate Council. She graduated Summa Cum Laude from Baylor University, and with High Honors at Baylor College of Medicine in Houston. After completing a fellowship in Hematology / Oncology at the University of Alabama at Birmingham (UAB), where she was a recipient of the American Society of Hematology (ASH) Travel Award. Dr. Gregg was an Assistant Professor at UAB and a member of the UAB Comprehensive Cancer Center. She subsequently joined Kelsey-Seybold Clinic, a multi-specialty clinic in Houston, Texas where she was Hematology / Oncology Section Chief – Cancer Liaison Physician for the American College of Surgeons’ Commission on Cancer, and was a Clinical Assistant Professor at Baylor College of Medicine. Dr. Gregg has served on the ASH Committee on Practice, as the Utah Medicare Carrier Advisory Committee Hematology Representative, and as a Blood reviewer. She was Co-Chair of the 2021 NCODA Fall Summit and 2022 Spring Forum meetings. She has published in peer-reviewed journals and major Hematology texts, including multiple editions of Williams’ Hematology and Hematology: Basic Principles and Practice



NCODA, Inc. is a 501(c)(3) organization. Our Mission is to empower the medically-integrated oncology team to deliver positive, patient-centered outcomes by providing leadership, expertise, quality standards and best practices. For more information about NCODA’s Executive Council and general updates, visit